Cipla could deliver healthy growth of 5% in the Indian business in the second quarter, but the US business is likely to witness pressure on account of lower Albuterol Sulphate sales. Revenue for the quarter is likely to grow at 13% year-on-year (YoY), according to an average estimate of three brokerages, and net profit for the same period is expected to rise around 19% YoY.
What should investors do with RIL stock? Rahul Sharma answers
Nifty definitely has been difficult in this month given the kind of correction that we have seen. So, we all know the reasons why it